The incidence of rash in the ECHO trial was lower among rilpivirine recipients than efavirenz recipients (4% versus 15%, P < 0.0001), 3 with grade 3 rash reported in one rilpivirine-treated patient and in two efavirenz-treated individuals, and no grade 4 rash was reported.
Of the two remaining participants, one had no change in the mild rhinorrhoea reported at baseline and one had an improvement in the pruritus and rash reported at baseline.
TEAEs of special interest included depression (reported in 2.7%, 2.3%, and 2.4% of the placebo, ESL 800 mg, and ESL 1,200 mg groups, respectively) and rash (reported in 1.8%, 1.4%, and 2.4% of the placebo, ESL 800 mg, and ESL 1,200 mg groups, respectively).
The other risks factors associated with the hepatotoxicity and/or rash reported in litterature, such as baseline HIV-1 RNA level, NVP plasma concentration, and genetic factors, could not be investigated in our study because there are not recorded in routine circumstances in Côte d'Ivoire.
No serious rashes were reported, and the incidence of withdrawals because of decreased seizure control was low (n = 2, or 3%; both incidents were judged to be related to noncompliance).
76 Some serious rashes were reported with febuxostat in the APEX study.
Five AEs were rashes, all reported by participants in the CYD-TDV group.
Rashes were reported in 25.0% and 22.6% of subjects in the HibMenCY-TT and Hib-OMP groups, respectively.
Rashes were reported in 8/311 children (2.6 %) in the ACWY-TT group and 1/103 child (1.0 %) in the MenC-CRM group and included dermatitis, eczema, rashes and skin exfoliation.
